40 officials held accountable in China for faulty vaccine scandal

Image
Press Trust of India Beijing
Last Updated : Aug 16 2018 | 6:35 PM IST

Over 40 Chinese government officials have been held accountable for their neglect of duty and misconduct for manufacturing substandard vaccines, including rabies vaccines, exported to India and other countries, in the country's latest drug-safety scandal.

Rabies vaccines made by the Changchun Changsheng Life Sciences Company, the second largest in China, were found to have violated national standards including usage of expired fluids and falsified production dates. The vaccines were also widely exported, including to India.

Forty government officials, including seven at the provincial level, have been held accountable for their neglect of duty or misconduct in oversight over the substandard vaccines at the company at a meeting presided over by Chinese President Xi Jinping, state-run Xinhua news agency reported today.

The Drug Controller General of India, early this month ordered an immediate withdrawal of rabies vaccines from the market and have also banned its imports from a Chinese manufacturer that allegedly fabricated records.

Also investigation by the Chinese officials into recent vaccine scandal revealed that the batch of DPT vaccines, produced in July 2016 by the Chinese firm were proved substandard due to a short-term equipment failure.

The DPT vaccines were made by Wuhan Institute of Biological Products Co. Ltd.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 16 2018 | 6:35 PM IST

Next Story